• A highly potent reversible and selective
• sodium-glucose co-transporter-2 inhibitor.
• For patients intolerant to metformin, it can be used as effective monotherapy.
• As monotherapy or combination therapy it provides effective glycermic contol and reduces body weight and blood pressure.
• In patients with type 2 diabetes who were risks for atherosclerotic CVD treatment with depagliflosin remitted in lower rate of hospitalization for heart failure.

In patients of diabetes with chronic kidney disease the risk of end stage kidney disease or death from renal or cardiovascular causes was significantly lowered with dapagliflozin.